Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 245

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years

Open access
Ioannou, Adam, Patel, Rishi K., Razvi, Yousuf, Porcari, Aldostefano, Sinagra, Gianfranco, Venneri, Lucia, Bandera, Francesco, Masi, Ambra, Williams, Georgina E., O’Beara, Sophie, Ganesananthan, Sharmananthan, Massa, Paolo, Knight, Daniel, Martinez-Naharro, Ana, Kotecha, Tushar, Chacko, Liza, Brown, James, Rauf, Muhammad U., Manisty, Charlotte, Moon, James, Lachmann, Helen, Wechelakar, Ashutosh, Petrie, Aviva, Whelan, Carol, Hawkins, Philip N., Gillmore, Julian D., Fontana, Marianna · 2022 · Circulation

Abstract

Background: Diagnostic and therapeutic advances have led to much greater awareness of transthyretin cardiac amyloidosis (ATTR-CA). We aimed to characterize changes in the clinical phenotype of patients diagnosed with ATTR-CA over the past 20 years. Methods: This is a retrospective observational cohort study of all patients referred to the National Amyloidosis Centre (2002–2021) in whom ATTR-CA was a differential diagnosis. Results: We identified 2995 patients referred with suspected ATTR-CA, of whom 1967 had a diagnosis of ATTR-CA confirmed. Analysis by 5-year periods revealed an incremental increase in referrals, with higher proportions of patients having been referred after bone scintigraphy and cardiac magnetic resonance imaging (2% versus 34% versus 51% versus 55%, chi-square P <0.001). This was accompanied by a greater number of ATTR-CA diagnoses, predominantly of the wild-type nonhereditary form, which is now the most commonly diagnosed form of ATTR-CA (0% versus 54% versus 67% versus 66%, chi-square P <0.001). Over time, the median duration of associated symptoms before diagnosis fell from 36 months between 2002 and 2006 to 12 months between 2017 and 2021 (Mann–Whitney P <0.001), and a greater proportion of patients had early-stage disease at diagnosis across the 5-year periods (National Amyloidosis Centre stage 1: 34% versus 42% versus 44% versus 53%, chi-square P <0.001). This was associated with more favorable echocardiographic parameters of structure and function, including lesser interventricular septal thickness (18.0±3.8 mm versus 17.2±2.6 mm versus 16.9±2.3 mm versus 16.6±2.4 mm, P =0.01) and higher left ventricular ejection fraction (46.0%±8.9% versus 46.8%±11.0% versus 47.8%±11.0% versus 49.5%±11.1%, P <0.001). Mortality decreased progressively during the study period (2007–2011 versus 2012–2016: hazard ratio, 1.57 [95% CI, 1.31–1.89], P <0.001; and 2012–2016 versus 2017–2021: hazard ratio, 1.89 [95% CI, 1.55–2.30], P <0.001). The proportion of patients enrolled into clinical trials and prescribed disease-modifying therapy increased over the 20-year period, but even when censoring at the trial or medication start date, year of diagnosis remained a significant predictor of mortality (2012–2016 versus 2017–2021: hazard ratio, 1.05 [95% CI, 1.03–1.07], P <0.001). Conclusions: There has been a substantial increase in ATTR-CA diagnoses, with more patients being referred after local advanced cardiac imaging. Patients are now more often diagnosed at an earlier stage of the disease, with substantially lower mortality. These changes may have important implications for initiation and outcome of therapy and urgently need to be factored into clinical trial design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.122.060852

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 245

Metadata

Authors
Ioannou, A., Patel, R. K., Razvi, Y., Porcari, A., Sinagra, G., Venneri, L., Bandera, F., Masi, A., Williams, G. E., O’Beara, S., Ganesananthan, S., Massa, P., Knight, D., Martinez-Naharro, A., Kotecha, T., Chacko, L., Brown, J., Rauf, M. U., Manisty, C., Moon, J., Lachmann, H., Wechelakar, A., Petrie, A., Whelan, C., Hawkins, P. N., Gillmore, J. D., & Fontana, M.
Venue
Circulation
Published
2022-11-29
Volume
146
Issue
22
Pages
1657-1670
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4308059498
Cited by
245
References
2
FWCI
13.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. https://app.cochat.ai/papers/10.1161/circulationaha.122.060852
The paper
Ioannou, A., Patel, R. K., Razvi, Y., Porcari, A., Sinagra, G., Venneri, L., Bandera, F., Masi, A., Williams, G. E., O’Beara, S., Ganesananthan, S., Massa, P., Knight, D., Martinez-Naharro, A., Kotecha, T., Chacko, L., Brown, J., Rauf, M. U., Manisty, C., . . . Fontana, M. (2022). Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation. https://doi.org/10.1161/circulationaha.122.060852

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.